Informed Consent
Item
provides written informed consent to participate in the study
boolean
C0021430 (UMLS CUI [1])
Age
Item
at least 18 but no more than 65 years old
boolean
C0001779 (UMLS CUI [1])
Multiple sclerosis relapse | Clinically isolated syndrome
Item
documented clinical diagnosis of a relapsing form of multiple sclerosis or confirmed clinically isolated syndrome (cis)
boolean
C0856120 (UMLS CUI [1])
C2921627 (UMLS CUI [2])
Betaseron Initiation | Betaseron Reuse
Item
initiating betaseron therapy, or resuming betaseron after not having used it for at least three months
boolean
C0284968 (UMLS CUI [1,1])
C1704686 (UMLS CUI [1,2])
C0284968 (UMLS CUI [2,1])
C2699072 (UMLS CUI [2,2])
E-mail Address Use of
Item
willing and able to provide a valid e-mail address which will be in use for the duration of the study
boolean
C1705961 (UMLS CUI [1,1])
C1524063 (UMLS CUI [1,2])
Clinical Trial Subject Questionnaire Completion Internet
Item
willing and able to complete study questionnaires via the internet
boolean
C3890411 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0282111 (UMLS CUI [1,3])
Availability of Internet Access
Item
has reliable internet access for the duration of the study
boolean
C0470187 (UMLS CUI [1,1])
C0282111 (UMLS CUI [1,2])
C0444454 (UMLS CUI [1,3])
Complete Patient Questionnaire Baseline
Item
completes the baseline patient questionnaire
boolean
C4289751 (UMLS CUI [1,1])
C1442488 (UMLS CUI [1,2])
EDSS
Item
kurtzke expanded disability status scale (edss) score greater than 6.0
boolean
C0451246 (UMLS CUI [1])
Impaired cognition Informed Consent Unlikely | Impaired cognition Complete Patient Questionnaire Unlikely
Item
cognitive dysfunction that, in the investigator's judgment, raises doubts about the study participant's ability to provide informed consent or accurately complete the monthly patient questionnaire
boolean
C0338656 (UMLS CUI [1,1])
C0021430 (UMLS CUI [1,2])
C0750558 (UMLS CUI [1,3])
C0338656 (UMLS CUI [2,1])
C4289751 (UMLS CUI [2,2])
C0750558 (UMLS CUI [2,3])
Betaseron Previous
Item
any use of betaseron within the three months prior to study entry
boolean
C0284968 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
Lacking Able to read English Language | Lacking Able to write English Language | Lacking Able to speak English Language
Item
inability to read, write, or speak the english language
boolean
C0332268 (UMLS CUI [1,1])
C0586740 (UMLS CUI [1,2])
C0376245 (UMLS CUI [1,3])
C0332268 (UMLS CUI [2,1])
C0584993 (UMLS CUI [2,2])
C0376245 (UMLS CUI [2,3])
C0332268 (UMLS CUI [3,1])
C0564215 (UMLS CUI [3,2])
C0376245 (UMLS CUI [3,3])
Illness Causing Patient Death | Disease Causing Patient Death | Illness Causing Patient Incapacity | Disease Causing Patient Incapacity | Exception Multiple Sclerosis
Item
illness or disease other than multiple sclerosis that the investigator believes is likely to cause the patient's death or incapacity within twelve months
boolean
C0221423 (UMLS CUI [1,1])
C0678227 (UMLS CUI [1,2])
C0030705 (UMLS CUI [1,3])
C0011065 (UMLS CUI [1,4])
C0012634 (UMLS CUI [2,1])
C0678227 (UMLS CUI [2,2])
C0030705 (UMLS CUI [2,3])
C0011065 (UMLS CUI [2,4])
C0221423 (UMLS CUI [3,1])
C0678227 (UMLS CUI [3,2])
C0030705 (UMLS CUI [3,3])
C3176592 (UMLS CUI [3,4])
C0012634 (UMLS CUI [4,1])
C0678227 (UMLS CUI [4,2])
C0030705 (UMLS CUI [4,3])
C3176592 (UMLS CUI [4,4])
C1705847 (UMLS CUI [5,1])
C0026769 (UMLS CUI [5,2])
Illness Severe Uncontrolled | Condition Severe Uncontrolled | Impact Patient Quality of life
Item
any severe, uncontrolled illness or condition that the investigator believes could dominate the patient's quality of life
boolean
C0221423 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0205318 (UMLS CUI [2,3])
C4049986 (UMLS CUI [3,1])
C0030705 (UMLS CUI [3,2])
C0034380 (UMLS CUI [3,3])
Autoimmune Disease | Rheumatoid Arthritis | Lupus Erythematosus | Psoriasis | Exacerbation Due to Interferon
Item
coexistent autoimmune disease such as rheumatoid arthritis, lupus, or psoriasis that is likely to be exacerbated by treatment with interferon
boolean
C0004364 (UMLS CUI [1])
C0003873 (UMLS CUI [2])
C0409974 (UMLS CUI [3])
C0033860 (UMLS CUI [4])
C4086268 (UMLS CUI [5,1])
C0678226 (UMLS CUI [5,2])
C3652465 (UMLS CUI [5,3])
Immunosuppressive Agents
Item
current use of any immunosuppressive medication
boolean
C0021081 (UMLS CUI [1])
Study Subject Participation Status | Multiple Sclerosis
Item
previous participation in a multiple sclerosis (ms) clinical trial within the three months prior to study entry
boolean
C2348568 (UMLS CUI [1])
C0026769 (UMLS CUI [2])
Monoclonal Antibodies Multiple Sclerosis
Item
previous use of monoclonal antibodies treating ms within the three months prior to study entry
boolean
C0003250 (UMLS CUI [1,1])
C0026769 (UMLS CUI [1,2])
Therapeutic procedure Secondary Multiple Sclerosis | Exception Steroids Relapse | Exception Steroids Exacerbation
Item
current use of any secondary treatment for multiple sclerosis other than the episodic use of steroids during relapses or exacerbations
boolean
C0087111 (UMLS CUI [1,1])
C0175668 (UMLS CUI [1,2])
C0026769 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0038317 (UMLS CUI [2,2])
C0035020 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0038317 (UMLS CUI [3,2])
C4086268 (UMLS CUI [3,3])